Robot maker · early
SquareMind
Paris medtech building Swan, a robotic-arm platform that autonomously captures standardized full-body dermoscopic images of a patient's skin; onboard AI plans the scan path around the body and software tracks new or changing moles over time, flagging risks for dermatologist review. Swan is CE-marked in Europe and FDA-listed as a Class I 510(k)-exempt device in the US, enabling sales in both regions. The April 2026 $18M round led by Fred Moll's Sonder Capital funds commercial launch in the US and Europe.
Company overview
Identity and operating footprint
Robot models
Specifications remain vendor-claimed
Swan
- First robot to capture standardized full-body dermoscopic images, with AI tracking of new or changing moles
Robotic dermatological imaging platform performing autonomous whole-body skin scans processed by AI for lesion monitoring
Claim source - CE-marked in Europe and FDA-listed Class I 510(k)-exempt in the US
Regulatory clearances permitting commercial sale in EU and US markets
Claim source
Funding history
Publicly announced rounds
Seed
Sonder Capital, Bpifrance (Deeptech 2030 Fund), Adamed Technology, Calm/Storm Ventures, Teampact Ventures
Round sourceCompany timeline
Milestones and announcements
Source ledger
2 unique public sources